Blood Research and EnhAnced Training against HIV in South Africa (BREATH-SA)

加州大学弗朗西斯科分校（UCSF）/Vitalant研究所（VRI）的更新，大学 开普敦（UCT）和南非国家血液服务（SANBS）血液研究和加强 南非艾滋病培训（BREATH-SA）计划将培训血液学家和血库， 开展高质量的艾滋病毒研究，以解决南非的相关研究问题。南非需要 正在进行的关于其艾滋病毒流行对艾滋病毒相关血液病和全国血液的影响的研究 供应该提案建立在SANBS 22年的艾滋病毒研究合作历史的基础上， UCSF/VRI和UCT在NHLBI资助的REDS-III国际艾滋病毒下的10年研究伙伴关系 研究网络。我们计划的前五年取得了实质性进展， 在南非国家统计局和UCT建立研究能力的具体目标，提供许多培训活动，毕业 13名硕士和博士生，并取得了强劲的出版记录。然而，我们的更新需求 评估表明，更好的职业支持、更多的辅导和更多的外联， 需要弱势机构来实现我们的总体目标，即建立可持续的 南非艾滋病相关输血医学和血液学研究企业的卓越成就。为此 更新，我们提出这些具体目标：1）培养下一代的临床研究人员在艾滋病毒血液学 和输血医学成为独立的研究人员，他们将解决新出现的健康挑战， 2）加强南非国家统计局艾滋病毒应用研究的机构研究能力， 发展学院和UCT血液学部的临床和转化艾滋病毒研究;以及3） 建立南非艾滋病毒血液学和输血医学卓越中心， 历史上处于不利地位的机构，并解决研究机会的不平等问题。我们计划一个四层 对各级受训人员的教育方法：关于临床研究方法的国内短期课程， 大量受训人员将参与方案设计和文稿编写工作; 在研究设计，生物统计学和数据分析的技能，我们建议在开普敦的中期课程工作， 旧金山弗朗西斯科;为最有前途的，硕士和博士学位招生卫生的UCT学校 科学;对于该计划的毕业生，一个新的早期调查员层提供职业指导， 大规模训练。所有学员将得到指导，因为他们完成研究项目，竞争迷你- 由该计划资助的赠款和出版手稿。研究资源包括艾滋病毒淋巴瘤登记处 UCT的临床资源，REDS-III HIV研究网络的存档数据和标本，以及真实的- 血液中心的HIV检测数据。高影响力的研究课题包括：艾滋病毒淋巴瘤生物学，临床 病程和治疗;艾滋病毒相关贫血和恶性肿瘤;使用新实验室的艾滋病毒流行率和发病率 艾滋病毒检测;抗逆转录病毒疗法对艾滋病毒检测的影响;以及艾滋病毒患者的适当输血疗法。

The renewal of the University of California San Francisco (UCSF)/Vitalant Research Institute (VRI), University of Cape Town (UCT) and South Africa National Blood Service (SANBS) Blood Research and EnhAnced Training against HIV in South Africa (BREATH-SA) program will train hematologists and blood bankers to perform high-quality HIV research to address relevant research questions in South Africa. South Africa needs ongoing research on its HIV epidemic’s impact on HIV-related hematologic diseases and the national blood supply. This proposal builds upon a 22-year history of HIV research collaboration between SANBS and UCSF/VRI and a 10-year research partnership with UCT under the NHLBI-funded REDS-III International HIV research network. The first five years of our program have made substantial progress towards our previous specific aims of building research capacity at SANBS and UCT, offering numerous training activities, graduating 13 Master’s and PhD students and achieving a robust publications record. However, our updated needs assessment has indicated that better career support, increased mentoring and more outreach to historically disadvantaged institutions is needed to achieve our overarching goal of creating sustainable centers of excellence in HIV-related transfusion medicine and hematology research enterprise in South Africa. For this renewal, we propose these Specific Aims: 1) Train the next generation of clinical researchers in HIV hematology and transfusion medicine to become independent researchers who will address emerging health challenges in these areas; 2) Strengthen institutional research capacity in applied HIV research at the SANBS Research and Development Academy and clinical and translational HIV research at the UCT Haematology Division; and 3) Develop a South African center of excellence in HIV hematology and transfusion medicine that will reach out to historically disadvantaged institutions and address inequities in research opportunity. We plan a four-tiered educational approach for trainees at various levels: in-country short courses on clinical research methodology, protocol design and manuscript preparation will reach a large number of trainees; for a smaller number lacking skills in study design, biostatistics and data analysis we propose medium-term course work in Cape Town and San Francisco; for the most promising, Master’s and PhD degree enrollment at the UCT School of Health Sciences; and for graduates of the program, a new early-stage investigator tier providing career mentorship and grantsmanship training. All trainees will be mentored as they accomplish research projects, compete for mini- grants funded by the program and publish manuscripts. Research resources include the HIV lymphoma registry and clinical resources at UCT, archived data and specimens from the REDS-III HIV research network and real- time HIV testing data from blood centers. High impact research topics include: HIV lymphoma biology, clinical course and treatment; HIV-related anemias and malignancies; HIV prevalence and incidence using novel lab assays; antiretroviral therapy’s impact on HIV testing; and appropriate transfusion therapy for HIV patients.